Praxis Precision Ownership
| PRAX Stock | USD 196.46 7.92 4.20% |
Praxis Stock Ownership Analysis
About 96.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.03. Praxis Precision Med recorded a loss per share of 12.97. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 29th of November 2023. Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. The company was incorporated in 2015 and is based in Boston, Massachusetts. Praxis Precision operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people. To find out more about Praxis Precision Medicines contact Marcio MBA at 617 300 8460 or learn more at https://praxismedicines.com.Praxis Precision Med Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Praxis Precision insiders, such as employees or executives, is commonly permitted as long as it does not rely on Praxis Precision's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Praxis Precision insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Praxis Precision Outstanding Bonds
Praxis Precision issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Praxis Precision Med uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Praxis bonds can be classified according to their maturity, which is the date when Praxis Precision Medicines has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PRAXAIR INC 355 Corp BondUS74005PBD50 | View | |
| US74005PBT03 Corp BondUS74005PBT03 | View | |
| PRAXAIR INC 32 Corp BondUS74005PBQ63 | View | |
| US74005PBS20 Corp BondUS74005PBS20 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Praxis Stock Analysis
When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.